KROS · Keros Therapeutics, Inc.
$11.03
+0.08 (+0.73%)
At close · Aug 21
Market Cap
$215.92M
Shares
19.83M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jasbir Seehra | President and Chief Executive Officer | $2,540,204 |
| Keith Regnante | Chief Financial Officer | $1,113,872 |
| Esther Cho | Esq. Chief Legal Officer Christopher Rovaldi Former President and Chief Operating Officer | $1,098,832 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Christopher Rovaldi | President and Chief Operating Officer | $6,975,416 |
| Jasbir Seehra | Ph.D. Chief Executive Officer and Chair Keith Regnante Chief Financial Officer | $6,273,192 |
| Yung Chyung | M.D. Chief Medical Officer | $5,641,367 |
| Keith Regnante | Chief Financial Officer | $2,292,177 |
| Simon Cooper | M.B.B.S. Former Chief Medical Officer | $1,760,775 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jasbir Seehra | Ph.D. Chief Executive Officer and Chair Keith Regnante Chief Financial Officer | $8,932,076 |
| Christopher Rovaldi | President and Chief Operating Officer | $4,688,165 |
| Simon Cooper | M.B.B.S. Former Chief Medical Officer | $2,245,597 |
| Keith Regnante | Chief Financial Officer | $2,197,414 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jasbir Seehra | Ph.D. Chief Executive Officer and Chair Keith Regnante Chief Financial Officer | $6,460,934 |
| Christopher Rovaldi | President and Chief Operating Officer | $4,247,354 |
| Simon Cooper | M.B.B.S. Former Chief Medical Officer | $2,313,467 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jasbir Seehra | Chief Executive Officer and Director | $7,233,959 |
| Keith Regnante | Chief Financial Officer | $3,047,555 |
| Jennifer Lachey | Chief Scientific Officer | $2,705,906 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jasbir Seehra | Chief Executive Officer and Director | $9,500,299 |
| Jennifer Lachey | Chief Scientific Officer | $3,542,278 |
| Keith Regnante | Chief Financial Officer | $2,363,042 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Jasbir Seehra | Chief Executive Officer and Director | $694,519 |
| Jennifer Lachey | Chief Scientific Officer | $414,294 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Annita Tanini | interim principal financial officer and principal accounting officer | Appointed | 2026-07-22 |
| Keith Regnante | Chief Financial Officer | Resigned | 2026-07-22 |
| Anne Prener, M.D., Ph.D. | director | Appointed | 2026-06-25 |
| Carl Gordon | director | Resigned | 2026-02-26 |
| Charles Newton | director | Appointed | 2026-02-26 |
| Ran Nussbaum | board of directors | Resigned | 2025-10-15 |
| Tomer Kariv | board of directors | Resigned | 2025-10-15 |
| Lorena Lerner | Chief Scientific Officer | Appointed | 2025-08-06 |
| Yung H. Chyung, M.D. | Chief Medical Officer | Resigned | 2025-07-15 |
| Yung H. Chyung, M.D. | Chief Medical Officer | Appointed | 2024-10-16 |
| Christopher Rovaldi | President | Appointed | 2024-06-17 |
| Jean-Jacques Bienaimé | Lead Independent Director | Appointed | 2024-06-17 |
| Carl L. Gordon | Chair of the Board | Resigned | 2024-06-17 |
| Jasbir Seehra | President | Resigned | 2024-06-17 |
| Jasbir Seehra | Chair of the Board | Appointed | 2024-06-17 |
| Jean-Jacques Bienaimé | director | Appointed | 2024-05-28 |
| Simon Cooper, M.B.B.S. | Chief Medical Officer | Resigned | 2024-03-05 |
| Alpna Seth | director | Appointed | 2023-04-19 |
| Christopher Rovaldi | Chief Operating Officer | Appointed | 2022-01-31 |
| Simon Cooper | Chief Medical Officer | Appointed | 2021-08-02 |
| Simon Cooper, M.B.B.S. | Chief Medical Officer | Appointed | 2021-08-02 |
| Alon Lazarus | director | Resigned | 2020-12-17 |
| Mary Ann Gray | director | Appointed | 2020-12-17 |
Key facts
CIK
1664710
CUSIP
492327101
13F (30d)
120 filings
119 filers
Visit website
Investor relations